Abcam

Cambridge, United Kingdom Founded: 1998 • Age: 28 yrs Acquired By Danaher
Biological reagents and antibodies are developed for life science research.
Request Access

About Abcam

Abcam is a company based in Cambridge (United Kingdom) founded in 1998 by Avner Dahan and Tony Kouzarides was acquired by Danaher in August 2023.. Abcam has raised $78.8 million across 6 funding rounds from investors including Danaher, HHS and National Science Foundation. Abcam has completed 12 acquisitions, including Ascent Scientific, AxioMx and BioVision. Abcam offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Abcam operates in a competitive market with competitors including Stem Cell Technologies, Meridian Bioscience, Teknova, Sangon Biotech and Cayman Chem, among others.

  • Headquarter Cambridge, United Kingdom
  • Founders Avner Dahan, Tony Kouzarides
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Abcam Limited
  • Date of Incorporation 12 Feb, 1998
  • Jurisdiction CAMBRIDGE, UNITED KINGDOM
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $78.8 M (USD)

    in 6 rounds

  • Latest Funding Round
    $258.66 M (USD), Debt – Conventional

    May 15, 2019

  • Investors
    Danaher

    & 2 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by
    Danaher

    (Aug 26, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Abcam

Abcam offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Antibodies for detecting specific proteins in biological samples

Kits for measuring proteins and analytes in research assays

Gene-edited cells for experimental and therapeutic studies

People of Abcam
Headcount 1000-5000
Employee Profiles 114
Board Members and Advisors 1
Employee Profiles
People
Michelle Chasmer
ER Specialist UK And EMEA
People
Nathan McNary
Senior Scientist (organic Chemistry)
People
S. Mandy Lund
Senior Scientist
People
Anusha Heuberger
Senior Scientist

Unlock access to complete

Board Members and Advisors
people
Giles Kerr
Non-Executive Director

Unlock access to complete

Funding Insights of Abcam

Abcam has successfully raised a total of $78.8M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $258.66 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Debt – Conventional — $258.7M
  • First Round

    (03 Aug 2009)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2019 Amount Debt – Conventional - Abcam Valuation

investors

Jul, 2013 Amount Grant - Abcam Valuation

investors

HHS
Apr, 2012 Amount Private Equity Round - Abcam Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Abcam

Abcam has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Danaher, HHS and National Science Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
A government-backed foundation providing seed-stage investments to support small businesses.
Founded Year Domain Location
Dental equipment and medical instruments are manufactured for therapeutic areas.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Abcam

Abcam has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include Ascent Scientific, AxioMx and BioVision. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Age-related disorders are addressed through senescent biology research.
2013
A recombinant antibody discovery and development platform is operated.
2012
Custom rabbit monoclonal antibodies are developed for research applications.
2012
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Abcam

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Abcam Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Abcam

Abcam operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Stem Cell Technologies, Meridian Bioscience, Teknova, Sangon Biotech and Cayman Chem, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of cell culture media and ancillary reagents for life science research
domain founded_year HQ Location
Molecular diagnostic device and kits
domain founded_year HQ Location
Molecular biology reagents and kits are supplied for research applications.
domain founded_year HQ Location
Research services, reagents, and kits for biotech applications are provided.
domain founded_year HQ Location
Bioreagents and assay kits are developed, with preclinical services provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Abcam

Frequently Asked Questions about Abcam

When was Abcam founded?

Abcam was founded in 1998 and raised its 1st funding round 11 years after it was founded.

Where is Abcam located?

Abcam is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.

Is Abcam a funded company?

Abcam is a funded company, having raised a total of $78.8M across 6 funding rounds to date. The company's 1st funding round was a Private Equity Round of $77M, raised on Aug 03, 2009.

What does Abcam do?

Abcam was founded in 1998 in Cambridge, United Kingdom, within the life sciences sector. Biological reagents are produced for research applications, encompassing primary and secondary antibodies, immunoassay kits, cellular imaging tools, biochemical assays, proteins, peptides, proteomic tools, agonists, antagonists, activators, inhibitors, lysates, and miRNA assays. Operations focus on supporting scientific investigations through these specialized products.

Who are the top competitors of Abcam?

Abcam's top competitors include Meridian Bioscience, Stem Cell Technologies and BBI Solutions.

What products or services does Abcam offer?

Abcam offers Primary Antibodies, ELISA Kits, and Cell Lines.

How many acquisitions has Abcam made?

Abcam has made 12 acquisitions, including Ascent Scientific, AxioMx, and BioVision.

Who are Abcam's investors?

Abcam has 3 investors. Key investors include Danaher, HHS, and National Science Foundation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available